StockData
Outlook Therapeutics, Inc. logo

Outlook Therapeutics, Inc. (OTLK) stock

OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 18, 2026Score 4/30
$0.36−0.04 (-8.94%)

Close on Nov 17, 2026Market cap $87.79MP/E –Yield –

Outlook Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Outlook Therapeutics's enterprise value was $78.75M on Nov 11, 2026, against $88.38M a year earlier. Over the last 5 years it ranged from $4.61M to $402.97M, with a median of $103.32M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$78.75M+2.2%
2025Dec 31, 2025$77.06M+154.7%
2024Dec 31, 2024$30.25M-61.8%
2023Dec 29, 2023$79.15M-65.3%
2022Dec 30, 2022$228.10M+1.1%
2021Dec 31, 2021$225.51M+47.6%
2020Dec 31, 2020$152.80M-85.9%
2019Dec 31, 2019$1.09B+3040.6%
2018Dec 31, 2018$34.56M+17.4%
2017Dec 29, 2017$29.43M-57.4%
2016Dec 30, 2016$69.10M–

More Outlook Therapeutics figures

See a number that looks wrong?